Shares of Bayer AG (FRA:BAYN) have received an average rating of “Buy” from the twenty-two brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is €122.32 ($151.01).
Several equities research analysts have recently issued reports on the company. Sanford C. Bernstein set a €129.00 ($159.26) price objective on Bayer and gave the company a “buy” rating in a research note on Friday, February 2nd. UBS Group set a €125.00 ($154.32) price objective on Bayer and gave the company a “buy” rating in a research note on Monday, February 5th. Baader Bank set a €140.00 ($172.84) price target on Bayer and gave the stock a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. set a €128.00 ($158.02) price target on Bayer and gave the stock a “buy” rating in a report on Tuesday, January 30th. Finally, Barclays set a €100.00 ($123.46) price target on Bayer and gave the stock a “sell” rating in a report on Monday, January 22nd.
Bayer (FRA BAYN) traded down €1.48 ($1.83) during trading hours on Friday, hitting €96.14 ($118.69). The stock had a trading volume of 6,034,400 shares. The company has a market cap of $78,820.00 and a price-to-earnings ratio of 22.73. Bayer has a 1-year low of €93.30 ($115.19) and a 1-year high of €123.82 ($152.86).
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.